{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:36:02Z","timestamp":1791974162415,"version":"4.4.0"},"reference-count":47,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment choices for colorectal peritoneal carcinomatosis\/metastases include systemic therapy and increasingly cytoreductive surgery with intraperitoneal chemotherapy delivery. These options are best considered as complementary and not exclusive alternatives. Two prospective randomized trials support use of peritonectomy procedures and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. This overview examines efficacy, limitations and landscape of systemic therapy focusing on colorectal peritoneal carcinomatosis. Observations from literature support notions that (1) systemic therapy provides survival benefit for all prototypical patients with mCRC irrespective of metastatic disease site; (2) the magnitude of this benefit is considerably reduced among patients with peritoneal metastases who consequently experience significantly shorter overall survival; (3) efficacy of systemic therapy improved over time but at a slower pace for those with carcinomatosis; (4) this therapeutic difference has not diminished with introduction of targeted therapy, but perhaps widened; (5) further research of cytoreductive surgery and\/or intraperitoneal regional therapies is thus a multidisciplinary responsibility of the entire oncology community; (6) peritonectomy procedures with intraperitoneal regional therapy are not scientifically supported in absence of systemic therapies.<\/jats:p>","DOI":"10.1515\/pp-2018-0102","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T10:58:38Z","timestamp":1522839518000},"source":"Crossref","is-referenced-by-count":36,"title":["Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: surgeon\u2019s perspective"],"prefix":"10.1515","volume":"3","author":[{"given":"Jan","family":"Franko","sequence":"first","affiliation":[{"name":"Chair of Surgical Oncology , Mercy Medical Center , 411 Laurel Street, Suite 2100 , Des Moines , IA 50314 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"2025120909183250339_j_pp-2018-0102_ref_001_w2aab3b7b3b1b6b1ab1b6b1Aa","unstructured":"Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Group EG-ITC, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft O, Australasian Gastro-Intestinal Trials G, Federation Francophone de Cancerologie D. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013;14:1208\u201315.10.1016\/S1470-2045(13)70447-924120480"},{"key":"2025120909183250339_j_pp-2018-0102_ref_002_w2aab3b7b3b1b6b1ab1b6b2Aa","unstructured":"Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. European Organisation for R, Treatment of C, Gastro-Intestinal Tract Cancer G, Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft O, National Cancer Research Institute Colorectal Clinical Study G. Local Treatment of Unresectable Colorectal Liver Metastases: results of a Randomized Phase II Trial. J Natl Cancer Inst 2017;109."},{"key":"2025120909183250339_j_pp-2018-0102_ref_003_w2aab3b7b3b1b6b1ab1b6b3Aa","unstructured":"NCCN Guidelines: Colon Cancer. 2018. Accessed February 4, 2018, 2018. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf.)"},{"key":"2025120909183250339_j_pp-2018-0102_ref_004_w2aab3b7b3b1b6b1ab1b6b4Aa","unstructured":"Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection\/ablation for colorectal liver metastases. Ann Surg 2004;239:818\u201325. discussion 25\u20137.1516696110.1097\/01.sla.0000128305.90650.71"},{"key":"2025120909183250339_j_pp-2018-0102_ref_005_w2aab3b7b3b1b6b1ab1b6b5Aa","unstructured":"Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052\u201361. discussion 61\u20134.1557021010.1097\/01.sla.0000145964.08365.01"},{"key":"2025120909183250339_j_pp-2018-0102_ref_006_w2aab3b7b3b1b6b1ab1b6b6Aa","unstructured":"Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309\u201318. discussion 18\u201321.10.1097\/00000658-199909000-0000410493478"},{"key":"2025120909183250339_j_pp-2018-0102_ref_007_w2aab3b7b3b1b6b1ab1b6b7Aa","unstructured":"Assersohn L, Norman A, Cunningham D, Benepal T, Ross PJ, Oates J. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer 1999;79:1800\u20135.1020629610.1038\/sj.bjc.6990287"},{"key":"2025120909183250339_j_pp-2018-0102_ref_008_w2aab3b7b3b1b6b1ab1b6b8Aa","doi-asserted-by":"crossref","unstructured":"Folprecht G, K\u00f6hne C-H LM. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. In: Ceelen WP, editor. Peritoneal carcinomatosis: a multidisciplinary approach. New York: Springer, 2007:425\u201340.","DOI":"10.1007\/978-0-387-48993-3_28"},{"key":"2025120909183250339_j_pp-2018-0102_ref_009_w2aab3b7b3b1b6b1ab1b6b9Aa","doi-asserted-by":"crossref","unstructured":"Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012;30:263\u20137.10.1200\/JCO.2011.37.103922162570","DOI":"10.1200\/JCO.2011.37.1039"},{"key":"2025120909183250339_j_pp-2018-0102_ref_010_w2aab3b7b3b1b6b1ab1b6c10Aa","doi-asserted-by":"crossref","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Analysis, research in cancers of the digestive system G. prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol 2016;17:1709\u201319.","DOI":"10.1016\/S1470-2045(16)30500-9"},{"key":"2025120909183250339_j_pp-2018-0102_ref_011_w2aab3b7b3b1b6b1ab1b6c11Aa","unstructured":"Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol 2012;38:617\u201323.2257210610.1016\/j.ejso.2012.03.008"},{"key":"2025120909183250339_j_pp-2018-0102_ref_012_w2aab3b7b3b1b6b1ab1b6c12Aa","unstructured":"Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989;63:364\u20137.291044410.1002\/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V"},{"key":"2025120909183250339_j_pp-2018-0102_ref_013_w2aab3b7b3b1b6b1ab1b6c13Aa","unstructured":"Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545\u201350.1244506410.1046\/j.1365-2168.2002.02274.x"},{"key":"2025120909183250339_j_pp-2018-0102_ref_014_w2aab3b7b3b1b6b1ab1b6c14Aa","unstructured":"Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006;243:212\u201322.10.1097\/01.sla.0000197702.46394.1616432354"},{"key":"2025120909183250339_j_pp-2018-0102_ref_015_w2aab3b7b3b1b6b1ab1b6c15Aa","unstructured":"Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358\u201363.1064096810.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O"},{"key":"2025120909183250339_j_pp-2018-0102_ref_016_w2aab3b7b3b1b6b1ab1b6c16Aa","unstructured":"Ceelen WP, Bracke ME. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol 2009;10:72\u20139.1911124710.1016\/S1470-2045(08)70335-8"},{"key":"2025120909183250339_j_pp-2018-0102_ref_017_w2aab3b7b3b1b6b1ab1b6c17Aa","unstructured":"Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124\u201332.785714110.1097\/00000658-199502000-00002"},{"key":"2025120909183250339_j_pp-2018-0102_ref_018_w2aab3b7b3b1b6b1ab1b6c18Aa","unstructured":"Francescutti V, Rivera L, Seshadri M, Kim M, Haslinger M, Camoriano M, et al. The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis. Oncol Rep 2013;30:35\u201342.10.3892\/or.2013.247323673557"},{"key":"2025120909183250339_j_pp-2018-0102_ref_019_w2aab3b7b3b1b6b1ab1b6c19Aa","unstructured":"Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681\u20135.1910372810.1200\/JCO.2008.19.7160"},{"key":"2025120909183250339_j_pp-2018-0102_ref_020_w2aab3b7b3b1b6b1ab1b6c20Aa","unstructured":"Cashin PH, Mahteme H, Spang N, Syk I, Frodin JE, Torkzad M, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. Eur J Cancer 2016;53:155\u201362.10.1016\/j.ejca.2015.09.01726751236"},{"key":"2025120909183250339_j_pp-2018-0102_ref_021_w2aab3b7b3b1b6b1ab1b6c21Aa","unstructured":"Verwaal VJ, Van Ruth S, De Bree E, Van Sloothen GW, Van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737\u201343.1455129310.1200\/JCO.2003.04.187"},{"key":"2025120909183250339_j_pp-2018-0102_ref_022_w2aab3b7b3b1b6b1ab1b6c22Aa","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:1386\u2013422.10.1093\/annonc\/mdw23527380959"},{"key":"2025120909183250339_j_pp-2018-0102_ref_023_w2aab3b7b3b1b6b1ab1b6c23Aa","unstructured":"Ryan D. Cytoreductive surgery and hyperthermic intraperitonal chemotherapy: history repeating itself or a new standard? In: ASCO 2011 educational book. American Society of Clinical Oncology 2011:127\u20138."},{"key":"2025120909183250339_j_pp-2018-0102_ref_024_w2aab3b7b3b1b6b1ab1b6c24Aa","doi-asserted-by":"crossref","unstructured":"Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Hj Z. 3rd. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 2010;116:3756\u201362.10.1002\/cncr.25116","DOI":"10.1002\/cncr.25116"},{"key":"2025120909183250339_j_pp-2018-0102_ref_025_w2aab3b7b3b1b6b1ab1b6c25Aa","unstructured":"Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baton O, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004;11:518\u201321.10.1245\/ASO.2004.09.00815123461"},{"key":"2025120909183250339_j_pp-2018-0102_ref_026_w2aab3b7b3b1b6b1ab1b6c26Aa","unstructured":"Verwaal VJ, Van Tinteren H, Van Ruth S, Zoetmulder FA. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739\u201346.1516444510.1002\/bjs.4516"},{"key":"2025120909183250339_j_pp-2018-0102_ref_027_w2aab3b7b3b1b6b1ab1b6c27Aa","unstructured":"Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and\/or irinotecan-based chemotherapy. Br J Cancer 2009;100:881\u20137.10.1038\/sj.bjc.660495519259089"},{"key":"2025120909183250339_j_pp-2018-0102_ref_028_w2aab3b7b3b1b6b1ab1b6c28Aa","unstructured":"Hugen N, Van De Velde CJ, De Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol 2014;25:651\u20137.2450444710.1093\/annonc\/mdt591"},{"key":"2025120909183250339_j_pp-2018-0102_ref_029_w2aab3b7b3b1b6b1ab1b6c29Aa","unstructured":"Klaver YL, Lemmens VE, Creemers GJ, Rutten HJ, Nienhuijs SW, De Hingh IH. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol 2011;22:2250\u20136.10.1093\/annonc\/mdq76221345939"},{"key":"2025120909183250339_j_pp-2018-0102_ref_030_w2aab3b7b3b1b6b1ab1b6c30Aa","unstructured":"Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, De Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011;128:2717\u201325.10.1002\/ijc.2559620715167"},{"key":"2025120909183250339_j_pp-2018-0102_ref_031_w2aab3b7b3b1b6b1ab1b6c31Aa","unstructured":"Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012;99:699\u2013705.10.1002\/bjs.867922287157"},{"key":"2025120909183250339_j_pp-2018-0102_ref_032_w2aab3b7b3b1b6b1ab1b6c32Aa","doi-asserted-by":"crossref","unstructured":"Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer 2013;108:1432\u20139.2351156410.1038\/bjc.2013.82","DOI":"10.1038\/bjc.2013.82"},{"key":"2025120909183250339_j_pp-2018-0102_ref_033_w2aab3b7b3b1b6b1ab1b6c33Aa","unstructured":"Demtr\u00f6der C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis 2016;18:364\u201371.2640055610.1111\/codi.13130"},{"key":"2025120909183250339_j_pp-2018-0102_ref_034_w2aab3b7b3b1b6b1ab1b6c34Aa","doi-asserted-by":"crossref","unstructured":"Hill M, Norman A, Cunningham D, Findlay M, Watson M, Nicolson V, et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 1995;13:2317\u201323.10.1200\/JCO.1995.13.9.23177666089","DOI":"10.1200\/JCO.1995.13.9.2317"},{"key":"2025120909183250339_j_pp-2018-0102_ref_035_w2aab3b7b3b1b6b1ab1b6c35Aa","unstructured":"Kouri M, Pyrhonen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 1992;49:78\u201385.10.1002\/jso.29304902041738240"},{"key":"2025120909183250339_j_pp-2018-0102_ref_036_w2aab3b7b3b1b6b1ab1b6c36Aa","unstructured":"Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229\u201337.1465722710.1200\/JCO.2004.05.113"},{"key":"2025120909183250339_j_pp-2018-0102_ref_037_w2aab3b7b3b1b6b1ab1b6c37Aa","unstructured":"Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370:135\u201342.10.1016\/S0140-6736(07)61086-1"},{"key":"2025120909183250339_j_pp-2018-0102_ref_038_w2aab3b7b3b1b6b1ab1b6c38Aa","unstructured":"Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. National cancer research institute colorectal clinical studies G. different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370:143\u201352.10.1016\/S0140-6736(07)61087-3"},{"key":"2025120909183250339_j_pp-2018-0102_ref_039_w2aab3b7b3b1b6b1ab1b6c39Aa","unstructured":"Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23:9441\u20132.1636164910.1200\/JCO.2005.04.4792"},{"key":"2025120909183250339_j_pp-2018-0102_ref_040_w2aab3b7b3b1b6b1ab1b6c40Aa","unstructured":"Hugen N, Verhoeven RH, Lemmens VE, Van Aart CJ, Elferink MA, Radema SA, et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. Int J Cancer 2015;136:333\u20139.2484186810.1002\/ijc.28981"},{"key":"2025120909183250339_j_pp-2018-0102_ref_041_w2aab3b7b3b1b6b1ab1b6c41Aa","unstructured":"Verwaal VJ, Bruin S, Boot H, Van Slooten G, Van Tinteren H. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426\u201332.1852168610.1245\/s10434-008-9966-2"},{"key":"2025120909183250339_j_pp-2018-0102_ref_042_w2aab3b7b3b1b6b1ab1b6c42Aa","unstructured":"Kennecke H, Yu J, Gill S, Cheung WY, Blanke CD, Speers C, et al. Effect of M1a and M1b category in metastatic colorectal cancer. Oncologist 2014;19:720\u20136.2489964210.1634\/theoncologist.2013-0442"},{"key":"2025120909183250339_j_pp-2018-0102_ref_043_w2aab3b7b3b1b6b1ab1b6c43Aa","unstructured":"Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017;18:1159\u201371.10.1016\/S1470-2045(17)30457-628781171"},{"key":"2025120909183250339_j_pp-2018-0102_ref_044_w2aab3b7b3b1b6b1ab1b6c44Aa","doi-asserted-by":"crossref","unstructured":"Kemeny NE, Chou JF, Boucher TM, Capanu M, DeMatteo RP, Jarnagin WR, et al. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol 2016;113:477\u201384.10.1002\/jso.2418926830685","DOI":"10.1002\/jso.24189"},{"key":"2025120909183250339_j_pp-2018-0102_ref_045_w2aab3b7b3b1b6b1ab1b6c45Aa","doi-asserted-by":"crossref","unstructured":"Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004;11:178\u201386.10.1245\/ASO.2004.05.00914761921","DOI":"10.1245\/ASO.2004.05.009"},{"key":"2025120909183250339_j_pp-2018-0102_ref_046_w2aab3b7b3b1b6b1ab1b6c46Aa","unstructured":"Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350\u20136.10.1038\/nm.396726457759"},{"key":"2025120909183250339_j_pp-2018-0102_ref_047_w2aab3b7b3b1b6b1ab1b6c47Aa","unstructured":"Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, et al. (Non-V600) BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J Clin Oncol 2017;35:2624\u201330.2848604410.1200\/JCO.2016.71.4394"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/3\/1\/article-20180102.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0102\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:24:02Z","timestamp":1765272242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0102\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3,30]]},"published-print":{"date-parts":[[2018,3,26]]}},"alternative-id":["10.1515\/pp-2018-0102"],"URL":"https:\/\/doi.org\/10.1515\/pp-2018-0102","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,1]]},"article-number":"20180102"}}